James Brashears, MD
Radiation Oncology · Seattle, WANPI 1720177819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $473 and has fallen 77.2% since, to $108 in 2025.
Across 25 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myovant Sciences Inc.$125
- Sumitomo Pharma America, Inc.$108
- Boston Scientific$49
- Tesaro, Inc.$45
- Bristol Myers Squibb$43
- Blue Earth Diagnostics$36
- plus $315 from 15 others
What the payments were for
- Food & beverage$721100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myovant Sciences Inc. | 2 | $125 |
| Sumitomo Pharma America, Inc. | 2 | $108 |
| Boston Scientific | 1 | $49 |
| Tesaro, Inc. | 1 | $45 |
| Bristol Myers Squibb | 2 | $43 |
| Blue Earth Diagnostics | 1 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $31 |
| Boehringer Ingelheim | 1 | $27 |
| Exelixis Inc. | 1 | $26 |
| Bayer | 1 | $24 |
| Amgen | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Sanofi | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Novocure Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$110
How this compares
$721 in reported general payments places this provider in the 65th percentile of 168 radiation oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 23 | $203 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Seattle
- Vivek MehtaSeattle$120K
- Christopher LoiselleSeattle$63K
- Ramesh RenganSeattle$57K
- Jing ZengSeattle$37K
- Omar MianSeattle$22K
- Richard HsiSeattle$18K
- Michael FolkertSeattle$11K
- Kent WallnerSeattle$9K
- Robert MeierSeattle$8K
- Shannon FoghSeattle$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.